期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 14, 期 8, 页码 15636-15654出版社
MDPI
DOI: 10.3390/ijms140815636
关键词
CA125; N-glycosylation; biomarker; ovarian cancer
资金
- European Union [260600]
- Science Foundation Ireland, Strategic Research Cluster Award [08/SRC/B1410]
Ovarian cancer is the most lethal gynaecologic cancer affecting women. The most widely used biomarker for ovarian cancer, CA125, lacks sensitivity and specificity. Here, we explored differences in glycosylation of CA125 between serum from patients with ovarian cancer and healthy controls. We found differences between CA125 N-glycans from patient sera compared to controls. These include increases in core-fucosylated bi-antennary monosialylated glycans, as well as decreases in mostly bisecting bi-antennary and non-fucosylated glycans in patients compared to controls. Measurement of the glycosylated state of CA125 may therefore provide a more specific biomarker for patients with ovarian cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据